ST
The startup develops antibody-based biologics targeting a protein that promotes vascular destabilization, specifically for applications in nephrology, oncology, and ophthalmology. This approach enhances the vascularization of solid tumors, improving the delivery and efficacy of small molecules, biologics, and cell therapies.
Updated 3 months ago
Funding
$720K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops antibody-based biologics targeting a protein that promotes vascular destabilization, specifically for applications in nephrology, oncology, and ophthalmology. This approach enhances the vascularization of solid tumors, improving the delivery and efficacy of small molecules, biologics, and cell therapies.